Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

Milton Keynes Health Economy

Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. January 2019
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	***Date of TA Release***	***Availability of medicine for NHS patients with this medical condition, as indicated by NICE***	***Adherence of local formulary to NICE***				
			Yes *(mark 'x' if applicable)*	***N/A*** *(mark 'x' if applicable)*	***Date of local decision*** *(DD/MM/YY)*	***Time to implement*** *(days)*	***Notes*** *(e.g. rationale, method of making available)*
2018/2019							
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)	10/01/2019	Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (See criteria via link)	x		23/01/2019		NHSE / CDF commissioned. Approved for addition to the formulary and to be used in line with NICE TA557 and commissioning statements
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)	09/01/2019	Darvadstrocel is not recommended, within its marketing authorisation, for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease.	x		23/01/2019		Not recommended
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)	09/01/2019	Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had sorafenib (SEE CRITERIA VIA LINK)	x		23/01/2019		NHSE / CDF commissioned. Approved for addition to the formulary and to be used in line with NICE TA555 and commissioning statements
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)	21/12/2018	Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	x		23/01/2019		NHSE / CDF commissioned. Approved for addition to the formulary and to be used in line with NICE TA554 and commissioning statements
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)	19/12/2018	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection	x		23/01/2019		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA553 and commissioning statements

Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)	19/12/2018	Liposomal cytarabine–daunorubicin is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-	x		23/01/2019		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA552 and commissioning statements
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)	19/12/2018	Lenvatinib is recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults (see criteria via link)	x		23/01/2019		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA551 and commissioning statements
Vandetanib for treating medullary thyroid cancer (TA550)	12/12/2018	Vandetanib is not recommended, within its marketing authorisation, for treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.	X		23/01/2019		Not recommended
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)	05/12/2018	NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen	X		23/01/2019		Terminated Appraisal
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)	05/12/2018	NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was received from Janssen.	X		23/01/2019		Terminated Appraisal
Tofacitinib for moderately to severely active ulcerative colitis (TA547)	28/11/2018	Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment.	x		23/01/2019		CCG commissioned. Approved for addition to the formulary and to be used in line with NICE TA547 and commissioning statements; Blueteq form required
Padeliporfin for untreated localised prostate cancer (TA546)	21/11/2018	Padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults	X		23/01/2019		Not recommended

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)	14/11/2018	Gemtuzumab ozogamicin, with daunorubicin and cytarabine, is recommended as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia, in people 15 years and over	X		23/01/2019		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA545 and commissioning statements
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)	17/10/2018	Dabrafenib with trametinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults	X		28/11/2019		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA544 and commissioning statements
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)	03/10/2018	Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: (see criteria via link)	x		28/11/2018	56	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE TA543 and commissioning statements
Cabozantinib for untreated advanced renal cell carcinoma (TA542)	03/10/2018	Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma	X		28/11/2018	56	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA542 and commissioning statements
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)	19/09/2018	Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults.	x		28/11/2018		NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA541 and commissioning statements
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)	03/09/2018	Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin	x		26/09/2018	23	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA540 and commissioning statements
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)	29/08/2018	Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults	x		26/09/2018	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA539 and commissioning statements

Dinutuximab beta for treating neuroblastoma (TA538)	22/08/2018	Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy and stem cell transplant	x		26/09/2018	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE TA538 and commissioning statements
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)	08/08/2018	Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults	x		26/09/2018	49	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE TA537 and commissioning statements
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)	08/08/2018	Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults	x		26/09/2018	49	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)	08/08/2018	Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine	x		26/09/2018	49	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Dupilumab for treating moderate to severe atopic dermatitis (TA534)	01/08/2018	Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults	x		26/09/2018	56	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)	25/07/2018	Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features	x		26/09/2018	63	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Cenegermin for treating neurotrophic keratitis (TA532)	18/07/2018	Cenegermin is not recommended, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults	x		26/09/2018	70	Not recommended
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)	18/07/2018	Pembrolizumab is recommended as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations.	x		26/09/2018	70	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)	04/07/2018	Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy	x		25/07/2018	21	Not recommended
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)	04/07/2018	Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults	x		25/07/2018	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)	04/07/2018	Niraparib is recommended for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based	x		25/07/2018	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)	27/06/2018	Interferon beta-1a is recommended as an option for treating multiple sclerosis	x		25/07/2018	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)	13/06/2018	Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)	13/06/2018	Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)	13/06/2018	Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Midostaurin for untreated acute myeloid leukaemia (TA523)	13/06/2018	Midostaurin is recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)	13/06/2018	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Guselkumab for treating moderate to severe plaque psoriasis (TA521)	13/06/2018	Guselkumab is recommended as an option for treating plaque psoriasis in adults	x		25/07/2018	42	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)	16/04/2018	Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour),	x		23/05/2018	37	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)	25/04/2018	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy	x		23/05/2018	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements

Tocilizumab for treating giant cell arteritis (TA518)	18/04/2018	Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults	x		23/05/2018	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Avelumab for treating metastatic Merkel cell carcinoma (TA517)	11/04/2018	**Avelumab** is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.	x		23/05/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
			% "Yes"	**% "N/A"**	_	**Average implement time** (days)	
Adherence statistics for 2018-19			100%	0%		**41**	